2-(羧甲基)-4-氯苯甲酸 | 63177-08-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(羧甲基)-4-氯苯甲酸
• 英文名称: 2-(carboxymethyl)-4-chlorobenzoic acid
• 英文别名: 5-Chlorhomophthalsaeure；4-chloro-2-(carboxymethyl)benzoic acid；(2-carboxy-5-chloro-phenyl)-acetic acid；(2-Carboxy-5-chlor-phenyl)-essigsaeure；2-carboxymethyl-4-chlorobenzic acid；4-chlorohomophthalic acid
• CAS: 63177-08-2
• 化学式: C₉H₇ClO₄
• 分子量: 214.605
• InChiKey: WVTJEXSVQSHCPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(羧甲基)-4-氯苯甲酸 在 氯仿 、 四氯化碳 作用下， 以 乙酸酐 为溶剂， 反应 0.5h， 以to yield the 5-chlorohomophthalic anhydride melting at 170°-173°的产率得到6-chlorohomophthalic anhydride
  参考文献：
  名称：

  Aromatic dicarboxamides

  摘要：

  N-(4-氨基苯基)-芳香二酸亚胺，例如公式##STR1##中的化合物或其盐是抗癫痫药物。

  公开号：

  US04025505A1
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 生成 2-(羧甲基)-4-氯苯甲酸
  参考文献：
  名称：

  Tirouflet; Dabard, Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1958, vol. 246, p. 3255

  摘要：

  DOI：

文献信息

• Sulfones as Synthetic Linchpins: Transition‐Metal‐Free sp ³ –sp ² and sp ² –sp ² Cross‐Couplings Between Geminal Bis(sulfones) and Organolithium Compounds
  作者：Barry M. Trost、Christopher A. Kalnmals

  DOI：10.1002/chem.201800118

  日期：2018.6.26

  carbon of the bis(phenylsulfonyl)methyl unit to ultimately generate trisubstituted alkenes, comprising formal sp3–sp2 and sp2–sp2 cross‐couplings between organolithium reagents and bis(sulfones). This process occurs almost instantaneously at −78 °C in the absence of any transition metals. By developing this curious transformation, it has been demonstrated that bis(phenylsulfonyl)methane is a valuable

  据报道，一种有价值的抗药性策略突出了双（苯磺酰基）甲基合成子的歧义性质，并证明了其作为合成的关键物质的效用。尽管通常将双（苯磺酰基）甲基作为sp 3碳亲核试剂引入，但事实证明，在有机锂亲核试剂存在下，它也可以作为有效的sp 2碳亲电试剂起作用。烷基锂和芳基锂与双（苯磺酰基）甲基单元的中心碳偶合，最终生成三取代的烯烃，包括形式为sp 3 –sp 2和sp 2 –sp 2的烯烃。有机锂试剂和双（砜）之间的交叉偶联。在没有任何过渡金属的情况下，该过程几乎在-78°C下瞬间发生。通过发展这种奇怪的转变，已证明双（苯磺酰基）甲烷是一种有价值的合成链节，它可以经历两个CC键形成过程，即一个sp 3-亲核体，然后进行第三次CC键形成。反应作为有效的sp 2-亲电子试剂。此发现显着增强了这个普遍存在但未充分利用的链接器组的实用性。
• Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof
  申请人：Tsou Hwei-Ru

  公开号：US20080085890A1

  公开（公告）日：2008-04-10

  This invention provides compounds of Formula (I), having the structure where G 1 , G 2 , G 3 , G 4 , A 1 , A 2 , Y 1 , Y 2 , L 1 , Z, e and f are defined herein, or a pharmaceutically acceptable salt thereof, which are useful for treating or preventing cancer.

  这项发明提供了具有结构的化合物（I），其中G1、G2、G3、G4、A1、A2、Y1、Y2、L1、Z、e和f在此处定义，或其药用可接受盐，用于治疗或预防癌症。
• Phase-Transfer-Catalyzed Asymmetric Annulations of Alkyl Dihalides with Oxindoles: Unified Access to Chiral Spirocarbocyclic Oxindoles
  作者：Min Gao、Yongyi Li、Xuemin Li、Lin Hu

  DOI：10.1021/acs.orglett.1c04174

  日期：2022.1.28

  A general phase-transfer-catalyzed asymmetric (n+1) (n = 4 or 5) annulation reaction, featuring the direct coupling of simple oxindoles with alkyl dihalides that are allylic/benzylic and non-allylic/benzylic, has been developed to provide previously inaccessible cyclopentane- and cyclohexane-fused spirooxindole scaffolds with high yields and enantioselectivities (88–95% ee). Along with a broad scope

  已开发出一种通用的相转移催化不对称 ( n +1) ( n = 4 或 5) 环化反应，其特点是简单的羟吲哚与烯丙基/苄基和非烯丙基/苄基的烷基二卤化物直接偶联，以提供以前无法获得的环戊烷和环己烷融合的螺氧吲哚支架具有高产率和对映选择性（88-95% ee）。除了广泛的范围和温和的条件外，新协议还可以对药物 ubrogepant 的核心进行两步和克级合成。
• Nitrogen-containing heterocyclic compounds
  申请人：Yamanouchi Pharmaceutical Co., Ltd.

  公开号：US04163844A1

  公开（公告）日：1979-08-07

  Novel nitrogen-containing heterocyclic compounds shown by the formula ##STR1## wherein Y represents an oxygen atom, a sulfur atom, or a group shown by ##STR2## (wherein m is 1 or 2); n represents 0 or 1; R.sub.1 and R.sub.4, which may be the same or different, each represents a hydrogen atom, a lower alkyl group, or a lower alkenyl group; R.sub.2 and R.sub.3, which may be the same or different, each represents a hydrogen atom, a hydroxyl group, a lower alkanoyloxy group, a lower alkyl group or a lower alkenyl group; said R.sub.2 and R.sub.3 may further form together a double bond; R.sub.5 and R.sub.6, which may be the same or different, each represents a hydrogen atom, a halogen atom, a hydroxyl group, a nitro group, an amino group, a lower alkoxy group, a mono or di lower alkylamino group, or a lower alkyl group; said R.sub.5 and R.sub.6 may further form together a lower alkylenedioxy group; and R.sub.7 represents a hydrogen atom, a halogen atom, a lower alkanoyl group, a phenyl group, a phenyl lower alkyl group, a lower alkyl group, a hydroxy lower alkyl group, a di lower alkylamino lower alkyl group, a pyrrolidino lower alkyl group, a piperidino lower alkyl group, a morpholino lower alkyl group, or a 4-lower alkylpiperazino lower alkyl group; (1) when said R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 are hydrogen atom and n is 0, said Y is a group shown by ##STR3## and (2) when said R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.7 are hydrogen atom, at least one of said R.sub.5 and R.sub.6 is the aforesaid group other than hydrogen atom, and n is 0, said Y is oxygen atom or a group shown by ##STR4## and the pharmacologically acceptable non-toxic salts thereof. The compounds are strong analgesic anti-inflammatory agents.

  根据以下公式显示的新型含氮杂环化合物：其中Y代表氧原子、硫原子或由##STR2##所示的基团（其中m为1或2）；n代表0或1；R.sub.1和R.sub.4，可以相同也可以不同，分别代表氢原子、低烷基基团或低烯基基团；R.sub.2和R.sub.3，可以相同也可以不同，分别代表氢原子、羟基基团、低烷酰氧基团、低烷基基团或低烯基基团；所述的R.sub.2和R.sub.3还可以一起形成双键；R.sub.5和R.sub.6，可以相同也可以不同，分别代表氢原子、卤素原子、羟基基团、硝基基团、氨基基团、低烷氧基团、单或双低烷基氨基基团或低烷基基团；所述的R.sub.5和R.sub.6还可以一起形成低烷基二氧基基团；R.sub.7代表氢原子、卤素原子、低烷酰基团、苯基团、苯基低烷基基团、低烷基基团、羟基低烷基基团、双低烷基氨基低烷基基团、吡咯啉基低烷基基团、哌啶基低烷基基团、吗啉基低烷基基团或4-低烷基哌嗪基低烷基基团；（1）当所述的R.sub.1、R.sub.2、R.sub.3、R.sub.4、R.sub.5、R.sub.6和R.sub.7为氢原子且n为0时，所述的Y是由##STR3##所示的基团；（2）当所述的R.sub.1、R.sub.2、R.sub.3、R.sub.4和R.sub.7为氢原子，至少其中一个所述的R.sub.5和R.sub.6是上述的非氢原子基团，且n为0时，所述的Y是氧原子或由##STR4##所示的基团，以及其药理学上可接受的无毒盐。这些化合物是强效止痛抗炎剂。
• 1,3(2H,4H)-Dioxoisoquinoline-4-carboxamides used as anti-inflammatory
  申请人：Pfizer Inc.

  公开号：US03998954A1

  公开（公告）日：1976-12-21

  1,3(2H,4H)-Dioxoisoquinoline-4-carboxamides, nuclear unsubstituted and substituted, are prepared by reacting the appropriate homophthalimide with potassium cyanate. Secondary carboxamides are prepared by reacting homophthalimide with appropriate isocyanates, and tertiary carboxamides are prepared by aminolysis of 4-carbalkoxy compounds, which are in turn prepared by alcoholysis of the corresponding 4-carboxanilides. Corresponding 5,6,7,8-tetrahydro compounds are similarly prepared. The various 2-substituted homophthalimides are prepared by reacting homophthalic acid with appropriate amine. The 4-carboxamides are anti-inflammatory agents.

  1,3(2H,4H)-二氧化异喹啉-4-羧酰胺，核未取代和取代的，通过将适当的同间苯二酰亚胺与氰酸钾反应制备。次级羧酰胺是通过将同间苯二酰亚胺与适当的异氰酸酯反应制备的，而三级羧酰胺是通过对4-羧烷氧基化合物进行氨解制备的，这些化合物又是通过相应的4-羧基苯胺的醇解制备的。相应的5,6,7,8-四氢化合物同样制备。各种2-取代的同间苯二酰亚胺是通过将同间苯二甲酸与适当的胺反应制备的。4-羧酰胺是抗炎药物。